Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

PliaFX Flo Subtalar Fusion Study

16. november 2026 oppdatert av: Alastair Younger, St. Paul's Hospital, Canada

A Prospective Pilot Comparative Study to Evaluate the Efficacy of PliaFX® Flo Allograft in Subtalar Arthrodesis at St. Paul's Hospital in Vancouver, Canada

During a subtalar fusion, the bones making up the subtalar joint (talus and calcaneus) are permanently fused together. In the procedure, any damaged cartilage and bone at the subtalar joint is removed, then screws are inserted into the joint to fuse the bones together. Depending on the surgeon, a bone graft is sometimes applied between the bones prior to screw insertion to aid in bone bridging (growth of bone into the fusion site). Participants who consent to this study and are assigned to the PliaFX® Flo Allograft group, will receive PliaFX® Flo Allograft (human tissue donated from a donor) at the fusion site. The PliaFX® Flo system is demineralized bone fibers (hard minerals removed from bone using acid) in a sterile syringe that allows for delivery into small areas where bone graft is needed to assist bone fusion. The allograft bone fibers are produced from donated human cadaver (deceased human) bone.

This study aims to determine whether the use of PliaFX® Flo Allograft in subtalar fusions will improve functioning and healing of the bone and cartilage for patients like you. Participants who are interested will discuss with their surgeon and be randomly assigned to one of the two study procedures below. The patient will not know what group they are in until after all data has been collected and all study visits are complete.

Studieoversikt

Status

Har ikke rekruttert ennå

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

50

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • British Colombia
      • Vancouver, British Colombia, Canada, V6Z 1Y6
        • St. Paul's Hospital
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

19 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. The subject is at least 19 years of age.
  2. The subject is considered to be skeletally mature.
  3. The subject qualifies for subtalar fusion based on physical examination and/ or past medical history including isolated osteoarthritis, post-traumatic, degenerative, or rheumatoid arthritis of the ankle.
  4. The subject experiences severe pain in the subtalar joint that could not be cured with non-operative treatment options.
  5. The patient may undergo a subtalar fusion as part of a triple arthrodesis.
  6. The patient may have forefoot pathology addressed by either prior or concurrent surgery (osteotomies or fusions).
  7. The patient consented for either an arthroscopic or open procedure.
  8. The subject is able to comply with all post-operative evaluations and visits.
  9. The subject consents to and will receive either no graft or PliaFX® Flo allograft during their surgery

Exclusion Criteria:

  1. The subject has:

    • Severe osteoporosis
    • Neuromuscular impairment
    • Prior infection in the affected joint
  2. The subject currently has acute infections that, in the opinion of the Investigator, may complicate healing.

  3. The subject has a known or suspected allergy to any of the processing reagents listed in the packet insert (alcohol, glycinate buffer, and glycerol).

  4. The subject is renal compromised.

  5. The subject has a major risk factor for non-union (ex. poorly controlled diabetes or current smoker).

  6. The subject is undergoing a revision of a prior subtalar fusion.

  7. The subject has had a prior ankle joint fusion.

  8. An ankle joint replacement or ankle joint fusion may be performed during the same sitting.

  9. The subject has a BMI of > 50 kg/m2.

  10. The subject is known to be pregnant, or plans to become pregnant during the study period

  11. The investigator judges the subject to be unable or unlikely to remain compliant to follow-up due to a physical or mental condition (ex. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.).

  12. The subject is unable to provide informed consent.

  13. The subject is unable to communicate with the research team.

  14. The subject is unable to comply with follow-up.

  15. The subject has a history of substance addiction (e.g. recreational drugs, narcotics, or alcohol) within 12 months prior to screening for study entry

  16. The subject will be receiving a structural autograft or allograft (such as a femoral head graft or tri cortical iliac crest graft) to fill a defect greater than 1cm3

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Enhetens gjennomførbarhet
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PliaFX Flo Allograft

Participant will receive PliaFX Flo during their Subtalar Arthrodesis procedure.

Participant will receive the PliaFX Flo Allograft during their Subtalar Arthrodesis procedure.

Ingen inngripen: No Graft

Participant will receive no graft during their Subtalar Arthrodesis procedure.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Bone Bridging Percentage
Tidsramme: Enrollment to last Follow-up visit (52 weeks)

Bone bridging percentage measured by CT scans at 12, 24, and 52 weeks post-operatively.

Enrollment to last Follow-up visit (52 weeks)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Foot and Ankle Measure (FAAM) Questionnaire
Tidsramme: Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and lower scores are worse.

Enrollment to last follow up visit (52 weeks)
Current Health Assessment Questionnaire
Tidsramme: Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and higher scores are worse.

Enrollment to last follow up visit (52 weeks)
American Academy of Orthopaedic Surgeons (AAOS) Foot and Ankle Questionnaire
Tidsramme: Enrollment to last follow up visit (52 weeks)

Minimum value of 0, maximum value of 100, and lower scores are worse.

Enrollment to last follow up visit (52 weeks)
Demographics Questionnaire
Tidsramme: Enrollment to last follow up visit (52 weeks)
Enrollment to last follow up visit (52 weeks)
Ankle Osteoarthritis Scale
Tidsramme: Enrollment to last follow up visit (52 weeks)

Minimum value of 1, maximum value of 100, and higher scores are worse.

Enrollment to last follow up visit (52 weeks)
SF-36 Health Survey
Tidsramme: Enrollment to last follow up visit (52 weeks)
Enrollment to last follow up visit (52 weeks)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. desember 2030

Studiet fullført (Antatt)

1. desember 2031

Datoer for studieregistrering

Først innsendt

5. oktober 2026

Først innsendt som oppfylte QC-kriteriene

13. oktober 2026

Først lagt ut (Faktiske)

20. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • H26-01617

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere